Organon & Co.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.2B | $6.4B | $6.3B | $6.2B | $6.3B |
| Cost of revenue | $2.9B | $2.7B | $2.5B | $2.3B | $2.4B |
| Gross profit | $3.3B | $3.7B | $3.7B | $3.9B | — |
| Selling, general & administrative | $1.7B | $1.8B | $1.9B | $1.7B | $1.7B |
| Research and development | $366.0M | $469.0M | $528.0M | $471.0M | $443.0M |
| Interest expense | $504.0M | $520.0M | $527.0M | $422.0M | $258.0M |
| Pretax income | $425.0M | $807.0M | $673.0M | $1.1B | $1.5B |
| Income tax expense | $238.0M | -$57.0M | -$350.0M | $205.0M | $178.0M |
| Net income | $187.0M | $864.0M | $1.0B | $917.0M | $1.4B |
| Balance Sheet | |||||
| Cash and equivalents | $574.0M | $675.0M | $693.0M | $706.0M | $737.0M |
| Current assets | $4.4B | $4.3B | $4.5B | $3.9B | $3.8B |
| Total assets | $12.9B | $13.1B | $12.1B | $11.0B | $10.7B |
| Current liabilities | $2.4B | $2.7B | $2.9B | $2.5B | $2.6B |
| Total liabilities | $12.1B | $12.6B | $12.1B | $11.8B | — |
| Stockholders' equity | $752.0M | $472.0M | -$70.0M | -$892.0M | -$1.5B |
| Cash Flow Statement | |||||
| Cash from operations | $700.0M | $939.0M | $799.0M | $858.0M | $2.2B |
| Depreciation and amortization | $156.0M | $132.0M | $120.0M | $96.0M | $92.0M |
| Stock-based compensation | $77.0M | $105.0M | $101.0M | $75.0M | $59.0M |
| Capital expenditure | $162.0M | $175.0M | $251.0M | $196.0M | $192.0M |
| Free cash flow | $538.0M | $764.0M | $548.0M | $662.0M | $2.0B |
| Dividends paid | $88.0M | $297.0M | $294.0M | $290.0M | $145.0M |
| Impairments | $301.0M | $0 | $0 | $9.0M | $7.0M |
Shares outstanding 262.6M · Free float 98.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.